Navigation Links
Off-Label Stent Use: How Important Are FDA Approvals to Physicians?
Date:4/2/2008

Millennium Research Group survey finds that physicians place importance on

indication-specific FDA approval

WALTHAM, Mass., April 2, 2008 /PRNewswire/ -- Given the recent investigation by the US Department of Justice into the marketing of biliary stents for off-label uses in the peripheral vasculature, obtaining FDA approval for device use in specific arteries could become a key focus for stent manufacturers. A recent study conducted by Millennium Research Group at the Society of Interventional Radiology 33rd Annual Scientific Meeting in Washington, DC found that a significant portion of surveyed physicians would increase their use of biliary stents if the device received FDA approval for use in the peripheral vasculature; some physicians said their use could increase by as much as 50%.

Although stents on the market are only approved for use in the bile ducts, these stents have larger diameters than those used in coronary arteries, making them an attractive choice for physicians to use the peripheral arteries, such as the iliac artery. Once a stent has received pre-market approval from the FDA, physicians are free to use the stent off-label anywhere in the body; however, manufacturers can only promote the device for the specific indication(s) for which FDA approval has been granted.

Millennium Research Group's survey gauged the importance of FDA pre-market approval in physician decisions to use a particular stent brand, and also questioned physicians on whether or not they would be willing to pay a premium for a stent with artery-specific approval.

"The ability of a manufacturer to market FDA approval for a stent in a specific indication would provide physicians with increased confidence in the device's safety and efficacy," says Darren Navarro, Senior Analyst at Millennium Research Group. "Physician attitudes toward off-label use of stents may provoke new manufacturer initiatives to obtain artery-specific FDA approval. Furthermore, it may enable manufacturers to increase the price of their stents, growing revenues."

About Millennium Research Group

Millennium Research Group (http://www.MRG.net), a Decision Resources, Inc. company (http://www.DecisionResources.com), is the global authority on medical technology market intelligence and a leading provider of strategic information to the health care sector. Focused solely on the medical device, pharmaceutical, and biotechnology industries, the company provides its clients with the benefits of its specialized industry expertise through published reports, surveys, focus groups, and customized consulting services.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Amy Krohn

Millennium Research Group

416-364-7776 x101

akrohn@mrg.net


'/>"/>
SOURCE Millennium Research Group
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Real-World Data from ARRIVE Registries Show Favorable Outcomes for TAXUS(R) Express(TM) Stent
2. The Lancet Publishes Results From Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
3. OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM) is Feasible in Acute Myocardial Infarction Patients, American Heart Journal Paper Reports
4. Boston Scientific Announces Start of Major European Registry Assessing Different Olimus-Eluting Stents
5. Tryton Medical Receives CE Mark Approval for its Side-Branch Stent
6. CV Therapeutics and Medlogics Device Corporation Sign Licensing Agreement for CVTs Innovative Stent Coating Technology
7. Biosensors Receives CE Mark Approval for Its BioMatrix(R) Drug-Eluting Coronary Stent System
8. PCI Guideline Update Stresses Long-Term Anticoagulant Therapy After Treatment With Drug-Eluting Stents
9. ARRIVE Registry Analysis Demonstrates Continued Safety and Efficacy of TAXUS(R) Stent in Complex Real-World Patients
10. Preclinical Research on Coronary Stent with CeloNova BioSciences Polyzene(R)- F Nanocoating Receives Award at CIRSE 2007
11. Safety Profile of TAXUS(R) Liberte(TM) Stent System Highlighted in Worlds Largest Stent Registry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita ... miRNAs in people with peritoneal or pleural mesothelioma. Their findings are the subject of ... now. , Diagnostic biomarkers are signposts in the blood, lung fluid or tissue ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... 23, 2016 Houston Methodist Willowbrook Hospital ... Sports Association to serve as their official health ... Methodist Willowbrook will provide sponsorship support, athletic training ... association coaches, volunteers, athletes and families. ... Sports Association and to bring Houston Methodist quality ...
(Date:6/23/2016)... -- The Biodesign Challenge (BDC), a university competition that asks ... systems and biotechnology, announced its winning teams at the ... York City . The teams, chosen ... MoMA,s Celeste Bartos Theater during the daylong summit. Keynote ... of architecture and design, and Suzanne Lee , ...
Breaking Biology Technology:
(Date:4/15/2016)... , April 15, 2016  A new partnership ... more accurate underwriting decisions in a fraction of ... competitively priced and high-value life insurance policies to ... With Force Diagnostics, rapid testing (A1C, ... data readings (blood pressure, weight, pulse, BMI, and ...
(Date:4/13/2016)... CHICAGO , April 13, 2016  IMPOWER physicians ... are setting a new clinical standard in telehealth ... By leveraging the higi platform, IMPOWER patients can ... weight, pulse and body mass index, and, when they ... quick and convenient visit to a local retail location ...
(Date:3/29/2016)... , March 29, 2016 ... "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased to ... ink used in a variety of writing instruments, ensuring ... of originally created collectibles from athletes on LegacyXChange will ... analysis of the DNA. Bill Bollander ...
Breaking Biology News(10 mins):